Leerink initiated coverage of Sutro Biopharma (STRO) with an Outperform rating and $38 price target The company is focusing on novel approaches to optimize antibody drug conjugates to enhance the therapeutic window, the analyst tells investors in a research note. The firm believes Sutro’s mid-2026 data could de-risk STRO-004 and help validate its ADC platform.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STRO:
- Sutro Biopharma price target raised to $55 from $51 at Deutsche Bank
- Sutro Biopharma Faces Rising Operational Risks Amid Escalating U.S.-China Trade Tensions
- Sutro Biopharma upgraded to Buy from Neutral at H.C. Wainwright
- Wells upgrades Sutro to Overweight ahead of STRO-004 data
- Sutro Biopharma upgraded to Overweight from Equal Weight at Wells Fargo